/
Oncology
Colorectal Carcinoma
26
Pipeline Programs↗
40
Active Trials↗
28
Companies Involved↗
Colorectal Carcinoma is an emerging landscape with 26 programs across 28 companies. The most active players are Bexion Pharmaceuticals, Inc., AstraZeneca, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 211
Phase 37
Approved
No programs
Analysis
Modality Breakdown
21programs
Small molecule1257%
Monoclonal antibody943%
Modality classified for 88% of 26 pipeline programs.
Analysis
Trial Status
100
clinical trials
Completed39 · 39%
Recruiting24 · 24%
Unknown status10 · 10%
Terminated8 · 8%
Active, not recruiting7 · 7%
Not yet recruiting5 · 5%
Other7 · 7%
Clinical Trials
Trial Activity
100 trials
Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES)
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Preclinical·NCT06745895·350 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)